Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Massimo Cristofanilli(Cornell University), Dennis J. Slamon(University of California, Los Angeles), Sherene Loi(The University of Melbourne), Igor Bondarenko(Dnipro State Medical University), Nadia Harbeck(Breast Center), Cynthia Huang Bartlett(Pfizer (United States)), María Koehler(Pfizer (United States)), Marco Colleoni(European Institute of Oncology), Nicholas C. Turner(Institute of Cancer Research), Norikazu Masuda(Kyoto University), Seock‐Ah Im(Seoul National University), Yuqiu Jiang(Pfizer (United States)), Ke Zhang(Pfizer (United States)), Sunil Verma(VA Boston Healthcare System), Jungsil Ro(Western University), Angela DeMichele(University of Pennsylvania), Kathy Puyana Theall(Pfizer (United States)), Hiroji Iwata(Aichi Cancer Center)
The Lancet Oncology
March 2, 2016
10.1016/s1470-2045(15)00613-0
Cited by 1,819

Related Papers

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k